Therein lays my point. If the achievement of "mediocre" results...

Therein lays my point. If the achievement of "mediocre" results can double their SP overnight, what will excellent results achieve. Moreover, I'd expect than Genocea investors know who Admedus is. i dare say a few of them have their eye on our cheap valuation at present.

The results are probably good for exposure of the HSV Vax in general, and we may get a small free ride as far as marketing is concerned. I'd expect AHZ to get a mention as a competitor in Genocea Vax related articles. Independent journalism would probably also reference our interim results too. We'll see over the coming days. Watch the AEMUF ticker as well to see if volumes change and US interest in us picks up. Like you say Meomatta, interesting times ahead.